Back to top
more

Novartis (NVS)

(Real Time Quote from BATS)

$114.09 USD

114.09
1,028,949

+0.23 (0.20%)

Updated Oct 8, 2024 09:32 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 19% (47 out of 252)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Sheraz Mian headshot

Top Stock Analyst Reports for Microsoft, Facebook & Novartis

by Sheraz Mian

Today's Research Daily features new research reports on 16 major stocks, including Microsoft (MSFT), Facebook (FB) and Novartis (NVS).

Roche (RHHBY) 2019 Sales Solid on Robust Show by New Drugs

by Zacks Equity Research

Roche's (RHHBY) performance in 2019 is driven by solid strength in new drugs, which more than offset competition from biosimilars.

Incyte's Phase III Atopic Dermatitis Study Meets Primary Goal

by Zacks Equity Research

Incyte (INCY) posts positive top-line results from late-stage TRuE-AD2 study on ruxolitinib cream to treat adolescent and adult patients with atopic dermatitis. The study achieves its main goal.

Novartis (NVS) Earnings and Revenues Miss Estimates in Q4

by Zacks Equity Research

Novartis (NVS) reports disappointing results for the fourth quarter but provides an encouraging outlook for 2020.

Why Earnings Season Could Be Great for Novartis (NVS)

by Zacks Equity Research

Novartis (NVS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Jazz (JAZZ) Submits NDA for Xyrem Follow-On Candidate JZP-258 (Revised)

by Zacks Equity Research

Jazz (JAZZ) files regulatory application seeking approval for JZP-258, a low sodium formulation of Xyrem, in the United States.

Lilly (LLY) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

Eli Lilly and Company's (LLY) new drugs like Trulicity, Taltz and Jardiance are likely to have performed well. Let's see if these along with older products lead to an earnings beat for the company.

Kinjel Shah headshot

Pharma Stock Roundup: J&J's Mixed Q4, Roche & Novartis' New Drugs Approval in EU

by Kinjel Shah

J&J (JNJ) announces mixed Q4 results. Roche's (RHHBY) lymphoma drug, Polivy and Novartis' (NVS) Mayzent for secondary progressive multiple sclerosis (SPMS) get approval in Europe.

Jazz (JAZZ) Submits NDA for Xyrem Follow-On Candidate JZP-258

by Zacks Equity Research

Jazz (JAZZ) files regulatory application seeking approval for JZP-258, a low sodium formulation of Xyrem, in the United States.

Roche's Risdiplam Meets Primary Endpoint in Infants Study

by Zacks Equity Research

Roche's (RHHBY) risdiplam meets primary endpoint in FIREFISH study in infants with type 1 spinal muscular atrophy.

Novartis (NVS) Gets Approval for MS Drug Mayzent in Europe

by Zacks Equity Research

Novartis' (NVS) MS drug, Mayzent, obtains approval in Europe for the treatment of adult patients with secondary progressive multiple sclerosis.

Puma Biotech's (PBYI) Breast Cancer Drug Nerlynx Aids Growth

by Zacks Equity Research

Puma Biotech (PBYI) focuses on improving sales of its only marketed drug Nerlynx, which is approved for treating breast cancer. The drug's label expansion programs also look promising.

Jazz's (JAZZ) New Sleep Drug Sunosi Gets Approval in Europe

by Zacks Equity Research

Jazz (JAZZ) receives approval for Sunosi as a treatment for excessive daytime sleepiness in narcolepsy or obstructive sleep apnea patients in Europe.

Is Novartis AG (NVS) A Suitable Pick for Value Investors?

by Zacks Equity Research

Is Novartis AG (NVS) a great pick from the value investor's perspective right now? Read on to know more.

Will J&J (JNJ) Roll Out Pharma Q4 Earnings With a Beat?

by Zacks Equity Research

J&J's (JNJ) cancer drugs are expected to have contributed significantly to fourth-quarter 2019 earnings. Generic/biosimilar headwinds are expected to have hurt Pharma unit's sales.

Kinjel Shah headshot

Pharma Stock Roundup: LLY Dermira Buyout Offer, Pipeline & Regulatory Updates

by Kinjel Shah

Lilly (LLY) offers to buy Dermira for $1.1 billion. AstraZeneca (AZN) and AbbVie (ABBV) provide pipeline updates.

Alnylam Provides Preliminary Q4 Sales for Onpattro & Givlaari

by Zacks Equity Research

Alnylam (ALNY) announces preliminary results for the fourth quarter and 2019 and provides other updates.

Regeneron's Phase II Candidate Promising in Primary Analysis

by Zacks Equity Research

Regeneron (REGN) announces encouraging results from the phase II study on rare bone disease candidate.

The Zacks Analyst Blog Highlights: Novartis, McDonald's, Bristol-Myers Squibb, CME and UBS

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Novartis, McDonald's, Bristol-Myers Squibb, CME and UBS

Sheraz Mian headshot

Top Analyst Reports for Novartis, McDonald's & Bristol-Myers Squibb

by Sheraz Mian

Today's Research Daily features new research reports on 16 major stocks, including Novartis (NVS), McDonald's (MCD) and Bristol-Myers Squibb (BMY).

Incyte's (INCY) Itacitinib Fails in Late-Stage GVHD Study

by Zacks Equity Research

Incyte (INCY) fails to meet goals in the phase III study on itacitinib for the treatment of first-line acute GVHD.

Glaxo (GSK) Shares Continue to Witness Upside: Here's Why

by Zacks Equity Research

Glaxo's (GSK) successful product launches, increasing focus on the oncology area, and positive pipeline and regulatory updates are driving the stock.

    Global Blood (GBT) Shares Double in a Year, Focus on Oxbryta

    by Zacks Equity Research

    Shares of Global Blood Therapeutics (GBT) have gained in the past year as its lead candidate voxelotor gets FDA approval for the treatment of SCD in patients aged 12 years or above.

    Ekta Bagri headshot

    3 Biotech Stocks Likely to Maintain Solid Momentum in 2020

    by Ekta Bagri

    With the biotech sector gaining steam in recent times, we shortlist three biotech stocks that are set to maintain momentum in 2020.

    Epizyme (EPZM) Shares Soar on Lead Candidate's Progress

    by Zacks Equity Research

    Epizyme's (EPZM) shares soar year to date on positive developments for its lead pipeline candidate tazemetostat being evaluated for the treatment of solid tumors and hematological malignancies